This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A Study of Nivolumab or Placebo in Combination Wit...
Clinical trial

A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer (CheckMate 7DX)

Read time: 2 mins
Last updated:16th Dec 2019
Identifier: NCT04100018

The purpose of this study is to test the safety and effectiveness of nivolumab with docetaxel in men with advanced castration resistant prostate cancer who have progressed after second-generation hormonal manipulation

Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 984 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer
Estimated Study Start Date: December 16, 2019
Estimated Primary Completion Date: February 20, 2023
Estimated Study Completion Date: May 14, 2024

- Experimental:
Arm A: (nivolumab + docetaxel + prednisone)
- Active Comparator: Arm B: (placebo + docetaxel + prednisone)

Category Value
Date last updated at source 2019-09-23
Study type(s) Interventional
Expected enrolment 984
Study start date 2019-12-16
Estimated primary completion date 2023-02-20

View full details